FDA
-
-
-
-
-
-
-
Jefferies Assumes Liquidia Technologies (LQDA) at Buy
-
-
-
-
-
-
-
Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD
-
-
-
-
-
-
-
U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disea
-
-
-
-
-
-
-
Liquidia Technologies (LQDA) Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA (treprostinil) Inhalation Powder
-
-
-
-
-
-
-
LifeSci Capital Reiterates Outperform Rating on Liquidia Technologies (LQDA)
-
-
-
-
-
-
-
Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement
-
-
-
-
-
-
-
Liquidia Technologies (LQDA) PT Lowered to $17 at Jefferies
-
322,234 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

